Maraviroc for previously treated patients with R5 HIV-1 infection - Wikidata - awgldk - TriplyDB

Maraviroc for previously treated patients with R5 HIV-1 infection

Maraviroc for previously treated patients with R5 HIV-1 infection

http://www.wikidata.org/entity/Q34806062

about

HIV-1 entry inhibitors: an overview Maraviroc: a review of its use in HIV infection and beyond Biased and g protein-independent signaling of chemokine receptors Current perspectives on HIV-1 antiretroviral drug resistance CCR5 antagonism in HIV infection: current concepts and future opportunities HIV-1 entry inhibitors: recent development and clinical use Current and emerging strategies for the prevention of graft-versus-host disease Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions Can host receptors for fungi be targeted for treatment of fungal infections?Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody Clinical significance of HIV-1 coreceptor usage.Approved Antiviral Drugs over the Past 50 Years Bottlenecks in HIV-1 transmission: insights from the study of founder viruses Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV Is systems biology the key to preventing the next pandemic?Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009 Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses HIV tropism and decreased risk of breast cancer HIV-1 drug resistance and resistance testing.Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications Reliable genotypic tropism tests for the major HIV-1 subtypes Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Combinatorial approaches to the prevention and treatment of HIV-1 infection Closing the door to human immunodeficiency virus.Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data.The maraviroc expanded access program - safety and efficacy data from an open-label study.Understanding the HIV coreceptor switch from a dynamical perspective.HIV integrase inhibitors: a new era in the treatment of HIV.Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection.The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.

P2860

Q24645525-B09774A0-A37D-4260-8F6F-ECBA76124944 Q26778504-5FB4A302-34C8-4A64-915B-2518E39254CB Q26823970-B7367C98-04E7-4ECA-AEB3-25E76F5E80D3 Q26852626-87791434-3F93-4100-8355-2B49BE510B79 Q26865457-4142F98F-265E-4872-B18C-2F652D10AFEB Q27003887-CACCDAB3-6A58-43D0-9C8E-D4B4768FF0C2 Q27016541-807C9B1A-5F28-4C32-9B1D-2C195ED8CD77 Q27021524-0958E58F-BA05-4B7F-BF0B-5059615913E0 Q27026653-89883C46-4912-4247-B324-CDCBDD071447 Q27666197-8C22B980-5A18-4632-8707-E94BC0FB0C6F Q27691426-9E1AC347-2DE3-4034-8138-935345E28C81 Q27755387-543AE5E6-1161-4210-AEA9-C855D252E2F2 Q28082862-88CA3FDF-86D6-4BFD-8FCB-F8A9A637F305 Q28235281-2CC70ABD-C6D1-4014-85FB-BC8BD69ECED5 Q28473401-AC37EE6F-1781-4989-8F2F-5C5B303D7520 Q28475890-3C358300-EB5A-4849-B108-098745D84266 Q28476489-02A391E3-A500-4939-9D9D-20DF8717DD15 Q28547216-74465AE3-7EB6-4FB8-82F0-C1480E9CB30A Q28728667-43EAB32B-4E2A-41AC-A965-5BD0033F74AC Q28741704-0F90F861-F485-4922-98ED-5A20049D6669 Q28742018-BC5F69FA-F56A-4F73-A482-59EBFF1F46C3 Q28744167-8715E31A-9FDC-4C36-9F23-C730582A2393 Q30245693-8EFD54FA-194D-4FDC-A562-4D13A150E81A Q30366071-B3F00D03-F99F-4554-BE9E-5A2A475273CF Q30372085-F6802722-D418-4C87-B4BA-69C620B1482B Q30378764-89AD42F3-49D8-4A2D-96BA-0AC4B5DAF074 Q30400060-8EFA51CB-574D-4989-9D66-19D1AE223DC1 Q30428089-3CD8C167-A463-4DF2-86E7-54CE772A52C2 Q30564042-C089E3A1-1466-4A83-8A12-6782962684E6 Q30911112-7C295834-C1F2-4B62-9BD3-AA9B3186BD69 Q30931832-046EDA9C-297D-4D41-BFE3-103F3116FD2D Q30956943-581334F0-4F4D-49BC-9D09-5A5F403D0ABA Q31026698-40F23B3A-3489-4DB7-A5AA-2F7E3A850C35 Q31117473-929AE278-58A0-4FB7-8811-37858A1D0DAD Q33455862-9C244E7D-E2DF-424E-8EB2-91193AEBDE30 Q33501346-F27313EF-04F8-487E-B459-3A103AF1022B Q33558676-3A713691-808C-471F-BEDF-FC61050F04E6 Q33559216-3B6CCB85-CB2C-4DA1-99C9-D0BF30EDD5B0 Q33570897-2E72A563-BC28-4BD5-8FE1-BA0926905B9D Q33595068-FC74FAB8-84D5-4A5D-BDE7-EA28A1311997

P2860

Maraviroc for previously treated patients with R5 HIV-1 infection

http://www.wikidata.org/entity/Q34806062

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Maraviroc for previously treated patients with R5 HIV-1 infection

@ast

Maraviroc for previously treated patients with R5 HIV-1 infection

@en

Maraviroc for previously treated patients with R5 HIV-1 infection

@nl

type

label

Maraviroc for previously treated patients with R5 HIV-1 infection

@ast

Maraviroc for previously treated patients with R5 HIV-1 infection

@en

Maraviroc for previously treated patients with R5 HIV-1 infection

@nl

prefLabel

Maraviroc for previously treated patients with R5 HIV-1 infection

@ast

Maraviroc for previously treated patients with R5 HIV-1 infection

@en

Maraviroc for previously treated patients with R5 HIV-1 infection

@nl

P1433

Q34806062-F428392E-9A15-4BEA-AFD5-105C22690317

P1476

Q34806062-C51BAD60-728A-4F51-A85D-4C5821F058CB

P2093

Q34806062-0C20C645-CD99-416E-874F-8B9EBFE3C63A

Q34806062-330FA46E-8327-457E-88FE-7B68FE0D417A

Q34806062-383350CE-FB7B-4210-B29D-D914461DAE18

Q34806062-41FC3D63-2FF0-4972-9324-8187E122A630

Q34806062-5BC65D01-8B91-4A34-8E28-EF083C385968

Q34806062-686D849F-6A7B-4A2D-9737-3174A08BE207

Q34806062-6FDD0B68-6D20-4ADB-8949-D9E591C1BD45

Q34806062-775CB068-4FA1-48D2-A756-8785BF27BE90

Q34806062-7A30BAE0-A38B-4027-8E16-ECE82166036A

Q34806062-862F06A1-240F-4513-BFEB-249D23DAFC16

P2860

Q34806062-1ACE1B33-E330-4198-BC03-A530EEA506B4

Q34806062-1C798EC8-98C8-40D2-BFFF-E2BB5E6AD184

Q34806062-2457CD0C-F82E-4800-99A7-B461FD62B8F6

Q34806062-2934418D-0E14-4C65-B783-4C9A172B1925

Q34806062-2D3E0C72-4ED4-4541-B07B-48167EB4A3EC

Q34806062-2DF650C0-7978-4822-88F2-5CD75B26BAF6

Q34806062-3F6A6C4F-8F05-466F-ABB8-5B45F51A055D

Q34806062-445F4655-3641-47A9-A389-B2417BE78232

Q34806062-44B5DF96-F4EE-47C8-B775-5DCF38B93A2B

Q34806062-5E6C84E2-7F6F-498E-8841-E5D66B8D6CAB

P304

Q34806062-3F2BF3C6-7EC7-41B5-8EDF-33669ABE5B1A

P31

Q34806062-1536A9DE-04F4-42AF-A4F9-725055CA00BA

P356

Q34806062-6A26972C-D2DA-4F02-ABF5-81214B3AA973

P407

Q34806062-183D778A-BAC7-49AD-B8F8-E898321D8C87

P433

Q34806062-FB1056DB-B155-4F28-B2CA-7BE61672665D

P478

Q34806062-DB427C35-E0A3-4BE2-97B9-C27FCB53FF67

P50

Q34806062-3F201733-4E03-42CA-9310-D5F16C80D5F4

Q34806062-8DDD8F64-A688-4239-B80F-D73AAFB2C362

P577

Q34806062-E67B7659-1907-49A2-B375-CB30383DC04E

P698

Q34806062-6A88F752-F58F-4BC5-B27A-D232B866B900

P921

Q34806062-49C967BE-DF4B-4F73-82FB-438A1A54C16C

Q34806062-D32D921A-5647-4166-BE0B-F39236755C9B

P932

Q34806062-3FEC2224-69DF-40CA-9301-7BC84854F1E7

P356

P1433

The New England Journal of Medicine

P1476

Maraviroc for previously treated patients with R5 HIV-1 infection

@en

P2093

Anders Karlsson

http://www.w3.org/2001/XMLSchema#string

Andrzej Horban

http://www.w3.org/2001/XMLSchema#string

Caroline Ridgway

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Elna van der Ryst

http://www.w3.org/2001/XMLSchema#string

Howard Mayer

http://www.w3.org/2001/XMLSchema#string

Jacob Lalezari

http://www.w3.org/2001/XMLSchema#string

James Goodrich

http://www.w3.org/2001/XMLSchema#string

Jeffrey Nadler

http://www.w3.org/2001/XMLSchema#string

John B Montana

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

CCR5 deficiency increases risk of symptomatic West Nile virus infection

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

Raltegravir with optimized background therapy for resistant HIV-1 infection

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

P304

1429-1441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0803152

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Bonaventura Clotet Sala

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18832244

http://www.w3.org/2001/XMLSchema#string

P921

P932

3078519

http://www.w3.org/2001/XMLSchema#string